Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

The Lancet. Diabetes & Endocrinology
N ToftePRIORITY investigators

Abstract

Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microal...Continue Reading

Citations

Jul 4, 2020·Proteomics. Clinical Applications·Tianlin HeVera Jankowski
Jun 6, 2020·Hormones : International Journal of Endocrinology and Metabolism·Zoi KleinakiStavroula A Paschou
Jul 3, 2020·Molecular Diagnosis & Therapy·M Loredana Marcovecchio
Jul 28, 2020·Proteomics. Clinical Applications·Agnieszka LatosinskaJoost P Schanstra
Oct 9, 2020·Nature Reviews. Nephrology·Markus M Rinschen, Julio Saez-Rodriguez
Nov 27, 2020·Clinical Journal of the American Society of Nephrology : CJASN·Peter Rossing
May 16, 2020·Drug Discovery Today·Frederikke E SembachLisbeth N Fink
Feb 3, 2021·Acta Diabetologica·Federica BaruttaGabriella Gruden
Oct 8, 2020·Pharmacology & Therapeutics·Cosimo CosimatoThomas A Mavrakanas
Dec 31, 2020·International Journal of Molecular Sciences·Irina LousaAlice Santos-Silva
Feb 26, 2021·The FEBS Journal·Liad HindenGil Leibowitz
Mar 30, 2021·Expert Review of Proteomics·E MavrogeorgisJ Siwy
Apr 7, 2021·American Journal of Hypertension·Tianlin HeJoachim Beige
Apr 25, 2021·Kidney International·Justyna SiwyBernd Stegmayr
May 1, 2021·Journal of Clinical Medicine·Maxence Tailliar On Behalf Of The Groupe Coopératif Sur le Lupus Rénal Gclr
May 11, 2021·EClinicalMedicine·Ralph WendtUNKNOWN CRIT-COV-U investigators
Jun 3, 2021·International Journal of Molecular Sciences·Fábio TrindadeRui Vitorino
Jun 22, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Sok Cin TyeHiddo J L Heerspink
Jul 3, 2021·Pharmaceuticals·Nina Vodošek HojsRadovan Hojs
Jul 1, 2021·Expert Review of Proteomics·Qi Wu, Robert A Fenton
Jul 7, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Viktor Rotbain CurovicUNKNOWN DIRECT Programme Study Group
May 5, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Alberto OrtizUNKNOWN European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association—European Dialysis and
Aug 8, 2021·Cancers·Ayman BannagaRamesh P Arasaradnam
Aug 8, 2021·Nature Reviews. Nephrology·Megumi OshimaTakashi Wada
Aug 12, 2021·Scientific Reports·Eleni PetraJoachim Jankowski
Nov 4, 2021·Journal of Diabetes Science and Technology·Kuo Ren TanLian Leng Low
Nov 6, 2021·Molecular Metabolism·Shijia LiuDong Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.